Serum copeptin level can be a helpful biomarker in evaluation of myocardial perfusion scintigraphy results

Cardiology Journal

Volumn 23, Issue 1, 2016, Pages 71-77

  Ede, Hüseyin ^a   Karaçavuş, Seyhan ^a   Göçmen, Ayşe Yeşim ^a   Yaylak, Barış ^b   Akkaya, Süleyman ^b   Açıkgöz, Burak ^b   Çilek, Neslihan ^a   Kılıç, Mahmut ^a   Erbay, Ali Rıza ^a  

^a BOZOK UNIVERSITY   (Turkey)

^b Diyarbakir Gazi Yasargil Education and Research Hospital   (Turkey)

Author keywords

Copeptin; Coronary artery disease; Ischemia; Myocardial perfusion scintigraphy

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; CREATININE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THYROTROPIN; TRIACYLGLYCEROL; TROPONIN I; GLYCOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREADMILL TEST; BLOOD; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; EXERCISE TEST; HEART MUSCLE ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; REPRODUCIBILITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; UPREGULATION;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; EXERCISE TEST; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPONIN I; UP-REGULATION;

EID: 84960145743     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2015.0036     Document Type: Article

References (25)

1. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP//AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2012; 60: e44–e164.
2. Pakkal M, Raj V, McCann GP. Non-invasive imaging in coronary artery disease including anatomical and functional evaluation of ischaemia and viability assessment. Br J Radiol, 2011; 84: S280–S295.
3. Melikian N, De Bondt P, Tonino P et al. Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. J Am Coll Cardiol Intv, 2010; 3: 307–314.
4. Berman DS, Kang X, Slomka PJ et al. Underestimation of extent of ischemia by gated SPECT myocardial perfusion imaging in patients with left main coronary artery disease. J Nucl Cardiol, 2007; 14: 521–528.
5. DePuey EG. How to detect and avoid myocardial perfusion SPECT artifacts. J Nucl Med, 1994; 35: 699–702.
6. Ben-Haim S, Almukhailed O, Neill J et al. Clinical value of supine and upright myocardial perfusion imaging in obese patients using the D-SPECT camera. J Nucl Cardiol, 2014; 21: 478–485.
7. Karacavus S, Celik A, Tutus A, Kula M, Oguzhan A, Kalay N. Can left ventricular parameters examined by gated myocardial perfusion scintigraphy and strain echocardiography be prognostic factors for major adverse cardiac events? Hell J Nucl Med, 2014; 17: 10–11.
8. Worden NE, Lindower PD, Burns TL, Chatterjee K, Weiss RM. A second look with prone SPECT myocardial perfusion imaging reduces the need for angiography in patients at low risk for cardiac death or MI. J Nucl Cardiol, 2015; 22: 115–122.
9. Mueller C. Biomarkers and acute coronary syndromes: An update. Eur Heart J, 2014; 35: 552–556.
10. Lipinski MJ, Escárcega RO, D’Ascenzo F et al. A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. Am J Cardiol, 2014; 113: 1581–1591.
11. Cerqueira MD, Weissman NJ, Dilsizian V et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation, 2002; 105: 539–542.
12. Ficaro EP, Lee BC, Kritzman JN, Corbett JR. Corridor DM. The Michigan method for quantitative nuclear cardiology. J Nucl Cardiol, 2007; 14: 455–465.
13. Lang RM, Bierig M, Devereux RB et al. Chamber Quantification Writing Group, American Society of Echocardiography’s Guidelines and Standards Committee, European Association of Echocardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr, 2005; 18: 1440–1463.
14. Singh Ranger G. The physiology and emerging roles of antidiuretic hormone. Int J Clin Pract, 2002; 56: 777–782.
15. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006; 52: 112–119.
16. Finley IV JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonist for the treatment of heart failure and hyponatremia. Circulation, 2008; 118: 410–421.
17. Jochberger S, Morgenthaler NG, Mayr VD et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab, 2006; 91: 4381–4386.
18. Dunser MW, Mayr AJ, Ulmer H et al. Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation, 2003; 107: 2313–2319.
19. Wade CE, Claybaugh JR. Plasma renin activity, vasopressin concentration, and urinary excretory responses to exercise in men. J Appl Physiol, 1980; 49: 930–936.
20. Radke KJ, King KB, Blair ML, Fitzpatrick PG, Eldredge DH. Hormonal responses to the 6-minute walk test in women and men with coronary heart disease: A pilot study. Heart Lung, 2005; 34: 126–135.
21. Möckel M, Searle J. Copeptin-marker of acute myocardial infarction. Curr Atheroscler Rep, 2014; 16: 421.
22. Pozsonyi Z, Förhécz Z, Gombos T, Karádi I, Jánoskuti L, Prohászka Z. Copeptin (C-terminal pro arginine-vasopressin) is an ındependent long-term prognostic marker in heart failure with reduced ejection fraction. Heart Lung Circ, 2015; 24: 359–367.
23. Staub D, Morgenthaler NG, Buser C et al. Use of copeptin in the detection of myocardial ischemia. Clin Chim Acta, 2009; 399: 69–73.
24. Conti A, Mariannini Y, Canuti E et al. Nuclear scan strategy and outcomes in chest pain patients value of stress testing with dipyridamole or adenosine. World J Nucl Med, 2014; 13: 94–101.
25. Chen GB, Wu H, He XJ et al. Adenosine stress thallium-201 myocardial perfusion imaging for detecting coronary artery disease at an early stage. J Xray Sci Technol, 2013; 21: 317–322.